Ilan Gielchinsky

Ilan Gielchinsky

Auto-generated profile, based on publicly available information

Ilan Gielchinsky

Research Branch, Meuhedet Health Services, Tel-Aviv, Israel

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2018 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
MSMatthijs J. Scheltema
Matthijs J. Scheltema
JCJohn I. Chang
John I. Chang
WBWillemien van Den Bos
Willemien van Den Bos
IGIlan Gielchinsky
Ilan Gielchinsky
TNTuan V. Nguyen
Tuan V. Nguyen
PSPhillip D. Stricker
Phillip D. Stricker
Diagnostic and Interventional Radiology

29 November 2017 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
GGGil A. Geva
Gil A. Geva
IGIlan Gielchinsky
Ilan Gielchinsky
NANina Aviv
Nina Aviv
KMKlaas E. A. Max
Klaas E. A. Max
OGOfer N. Gofrit
Ofer N. Gofrit
Iddo Ben-DovIddo Ben-Dov
Iddo Ben-Dov
MicroRNA (miRNA) are short nucleotide strands with a regulatory function in the cell. Several miRNAs have been shown to be useful as biomarkers for different neoplasms. The aim of this project was to assess whether levels of miRNA in cell free urine could be used as a biomarker in transitional cell carcinoma (TCC). cDNA libraries were produced based on small RNAs in urine samples of fourteen TCC patients and twenty healthy volunteers. Resulting reads were deep sequenced on Illumina HiSeq sequencer with the intent of characterizing cell free urine miRNA profiles. A statistically significant difference was found for a single miRNA; miR-210 was > sixfold higher in the TCC group compared to the control group. Furthermore, we were able to produce a diagnostic score by summing of standardized levels of overexpressed miRNA. This score was considerably higher in TCC patients with a sensitivity of 0.93, specificity of 0.76 and negative predictive value > 0.97.

1 January 2023 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
IGIlan Gielchinsky
Ilan Gielchinsky
NLNaama Lev-Cohain
Naama Lev-Cohain
Introduction: Irreversible electroporation (IRE) technology for prostate cancer (PC) generates consecutive electrical pulses between pairs of electrodes which move through tumorous cells, irreversibly perforate their membranes and eventually lead to cell death, while avoiding tissue thermal effect. The technique is used for primary focal lesions as well as for focal salvage cases. This series reports short term oncological control, quality of life and safety results. Methods: Retrospective data were collected from 45 consecutive cases of primary (N=38) and salvage (N=7) PC patients treated with IRE. All patients had transperineal MRI/US fusion biopsy and PET-PSMA scan prior to treatment, to verify single lesion. Transperineal Nano-Knife IRE system was used in day-care theatre. Patients had 6 months mpMRI, blood PSA and 1 year confirmatory biopsy following procedure. Quality of life was recorded during the first year. Results: Median primary subgroup analysis (N=38): age 69 years, initial PSA 5.6 ng/dL, lesion size 0.8 mL and ISUP Group 2 (1– 3). Median salvage subgroup analysis (N=7): age 76 years, initial PSA 11.9 ng/dL, lesion size 2.0 mL and ISUP Group 4 (1– 5). Median catheter time 5 (3– 7) days. No Clavien–Dindo> 1 complications were reported nor re-admissions, incontinence, strictures or fistulas. 5% of patients were given PDE-5i drugs. Primary group PSA dropped by 39%, mpMRI clearance in 84%, out-field new lesion in 12%, in-field lesion in 4%. Biopsy at 1 year: 4 patients had out-field clinically significant PC, thus 3 had re-IRE and 1 had radiation therapy. Salvage subgroup MRI clearance was 60%, and 52% remained on active surveillance by 1 year. Conclusion: IRE treatment for focal PC is safe for primary and salvage cases, if done by a meticulously skilled and trained team, and under strict protocols. The short term oncological results are promising especially for primary lesions. Long term oncological results will be published over time.

10 October 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
IGIlan Gielchinsky
Ilan Gielchinsky
JCJohn Chang
John Chang
TCThomas Cusick
Thomas Cusick
WDWarick Delprado
Warick Delprado
QNQuoc Nguyen
Quoc Nguyen
PSPhillip D. Stricker
Phillip D. Stricker

1 October 2018 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
IGIlan Gielchinsky
Ilan Gielchinsky
MSMatthijs J Scheltema
Matthijs J Scheltema
TCThomas Cusick
Thomas Cusick
JCJohn Chang
John Chang
RSRon Shnier
Ron Shnier
PSPhillip D Stricker
Phillip D Stricker
Introduction: Three percent of all new diagnosed prostate cancer (PC) patients are under the age of 50. Multiparametric MRI (mpMRI) is considered as increasingly powerful tool for decision-making in diagnosis of PC and in some active surveillance protocols. Since prostate architecture changes with age, we evaluated the sensitivity of mpMRI to detect clinically significant PC in patients under the age of 50 compared to pair-matched older patients. Methods: Data from a prospective collected and ethics approved database were retrospectively analyzed. We reviewed 1,395 records of PC patients from the years 2012–2017, identifying those under the age of 50 who had radical prostatectomy as primary treatment, a pre-operative mpMRI, a full clinical data set and who had clinically significant cancer (N=51). Tumor size and International Society of Urological Pathology (ISUP) score pair-matching was performed for patients older than 55 years. Clinically significant cancer was defined as ISUP >2 or ISUP 2 with >5% Gleason 4. The sensitivity to detect clinically significant cancer with mpMRI was calculated using pre-operative Prostate Imaging Reporting and Data System (PI-RADS) score and whole-gland final pathology. Results: The median patient age in the young and older groups was 47 and 62, respectively. Both cohorts matched significantly regarding tumor volume (P =0.91) and ISUP score (P =1.0). The median PI-RADS score for the young group was 3, and 4 for the older group. The sensitivity for mpMRI, for PI-RADS 3,4 and 5 was 80.3% (95% CI 66.8%–90.1%) in the young group and 84.3% in the older group (95% CI 71.4%–92.9%), demonstrating no statistically significant difference (P=0.603). Sensitivity of mpMRI for PI-RADS 4,5 was 49.0% (95% CI 34.7%–63.4%) for the young group and 72.5% (95% CI 58.2%–84.1%) for the older group, which differ significantly (P=0.014). Conclusions: mpMRI may have a reduced sensitivity for detecting clinically significant PC in patients under the age of 50 for PI-RADS score 4,5 lesions. Many significant PC lesions were reported as PI-RADS 3 under the age of 50. We recommend that increased significance is placed on PI-RADS 3 lesions found in patients under the age of 50.

1 July 2017 in Journal of Endourology
Verified
Journal Article
Closed access
IGIlan Gielchinsky
Ilan Gielchinsky
DPDov Pode
Dov Pode
MDMordechai Duvdevani
Mordechai Duvdevani
VYVladimir Yutkin
Vladimir Yutkin
ELEzekiel H. Landau
Ezekiel H. Landau
OGOfer N. Gofrit
Ofer N. Gofrit
Purpose: Transurethral surgery has been traditionally done using the nonelectrolyte, isotonic 1.5% glycine solution as irrigation fluid. The emergence of modern technologies, which can be applied with electrolyte solutions, such as bipolar resection and LASER evaporation, as well as the worry of transurethral resection (TUR) syndrome have driven urologists away from glycine toward the use of physiologic solution. Differences in the transparencies of these fluids have not been studied. Materials and Methods: The ability to resolve two bars at 1 mm apart using a 30° cystoscope lens immersed in different solutions was studied. Physiologic solution, distilled water (DW), and 1.5% glycine solutions containing increasing concentrations of blood, from 0.5% to 2%, were tested. Solutions containing 2% blood were inspected with magnification and microscopy. Results: One-millimeter resolution was reached in as much as 2% blood in 1.5% glycine solution and as much as 1% blood in DW, but in none of the blood–saline solutions. Magnified and microscopic views of 2% blood solutions showed an even distribution of red blood cells (RBCs) in physiologic solution, clumps of RBCs in 1.5% glycine, and an almost complete hemolysis in DW. Conclusions: Glycine solution increases the transparency compared to physiologic solution or DW owing to the clumping of RBCs. When the risk of TUR syndrome is low, as in resection of bladder tumors or small prostates, we propose that 1.5% glycine solution should be preferred over saline, owing to its improved visibility.